Retinitis Pigmentosa Market

Market Overview:

The 7 major retinitis pigmentosa markets reached a value of US$ 9.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 17.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.99% during 2024-2034.

The retinitis pigmentosa market has been comprehensively analyzed in IMARC's new report titled "Retinitis Pigmentosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinitis pigmentosa is a group of genetic eye disorders that primarily affect the retina, which is the light-sensitive tissue at the back of the eye. It typically causes progressive degeneration of the photoreceptor cells in the retina, leading to vision loss and, eventually, blindness. The disorder affects rods and cones, the two types of photoreceptor cells responsible for vision in low-light and bright-light conditions, respectively. The ailment typically causes night blindness, followed by tunnel vision and loss of central vision. Various other symptoms include difficulty distinguishing colors, glare sensitivity, and reduced visual acuity. As the disease progresses, it can lead to more severe visual impairment. The ailment is typically diagnosed through a comprehensive eye examination that comprises a visual acuity test, a visual field test, an electroretinogram (ERG), and genetic testing to identify any known mutations associated with the disease. During the examination, an eye care professional will evaluate the health of the retina and look for characteristic changes, such as the presence of pigmentation and the thinning of blood vessels. They may also perform additional tests to assess visual function, such as color vision testing and contrast sensitivity testing.

The rising cases of mutations in various genes that are involved in the function and maintenance of the retina are primarily driving the retinitis pigmentosa market. Additionally, the increasing prevalence of several triggering factors, such as genetic predisposition, certain medical conditions like Usher syndrome, exposure to environmental toxins, etc., is also propelling the market growth. Besides this, the widespread adoption of antioxidant therapy that involves taking supplements, including vitamin C, vitamin E, coenzyme Q10, etc., to reduce the levels of oxidative stress in the retina is creating a positive outlook for the market. Moreover, the emerging popularity of retinal prostheses, which use electrical stimulation to activate the remaining cells in the retina, allowing patients to distinguish between light and dark, is acting as another significant growth-inducing factor. Apart from this, the rising usage of fundus photography in diagnosing the ailment by detecting changes in the appearance of the retina, such as the presence of bone spicules, is also augmenting the market growth. Furthermore, the escalating demand for RNA therapy to slow or halt the progression of the condition, as well as improve visual function and quality of life for affected individuals, is expected to drive the retinitis pigmentosa market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the retinitis pigmentosa market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for retinitis pigmentosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinitis pigmentosa market in any manner.

Recent Developments:

• In May 2024, Kiora Pharmaceuticals, Inc. published remarkable findings from the ABACUS-1 clinical trial, which show that their investigational medicine KIO-301 boosted brain activity in patients with retinitis pigmentosa. The outcomes indicated a statistically significant rise in activity inside the visual cortex, as evaluated by functional MRI.
• In February 2024, jCyte, Inc. announced the successful outcome of its pre-phase 3 Type B meeting with the US FDA on January 16, 2024. Furthermore, the company is preparing to launch its major US trial of jCell for retinitis pigmentosa in the second half of 2024.
• In June 2023, Aldeyra Therapeutics, Inc. reported positive top-line findings from the Phase 2 clinical study of intravitreal ADX-2191 (methotrexate injection, USP), an experimental therapeutic candidate, in patients with retinitis pigmentosa. Compared to the baseline, the clinical trial showed statistically significant improvement in retinal function across a variety of physiological and psychophysical tests.
• In May 2023, Endogena Therapeutics Inc. stated that it had completed patient enrollment prior to the schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa. The experiment involves 14 individuals with retinitis pigmentosa caused by any pathologic genetic mutation and is being undertaken at five sites in the United States.

Key Highlights:

• Retinitis Pigmentosa is the most prevalent inherited retinal dystrophy, affecting over 1.5 million individuals globally.
• Retinitis pigmentosa is generally categorized into syndromic and non-syndromic disease.
• Non-syndromic retinitis pigmentosa is the type of disease without systemic abnormalities, and it accounts for 70-80% of all cases.
• Patients with retinitis pigmentosa frequently suffer sleep difficulties due to a lack of photic input (as much as 76% of patients) and headaches.
• Retinitis Pigmentosa affects 1 in every 4000 people in the United States.

Drugs:

Botaretigene sparoparvovec, formerly known as AAV-RPGR, is an experimental gene therapy used to treat individuals with X-linked retinitis pigmentosa caused by disease-causing mutations in the eye-specific version of the RPGR gene (RPGR ORF15). Botaretigene sparoparvovec is designed to transfer functional copies of the RPGR gene to the subretinal area, helping to improve and/or preserve eyesight.

EA-2353 is a first-in-class small drug that specifically stimulates endogenous retinal stem and progenitor cells, allowing them to develop into photoreceptors and potentially preserve or restore visual function. This gene-independent therapeutic method has significant benefits for retinitis pigmentosa, which has numerous genetic origins.

jCell is a novel allogeneic cell treatment in late-stage clinical development for retinitis pigmentosa. The treatment is a minimally invasive intravitreal injection that can be administered under topical anesthesia. The primary mechanism of action is the persistent release of established neurotrophic factors, which reduce photoreceptor cell death and increase the function of remaining photoreceptors.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the retinitis pigmentosa market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the retinitis pigmentosa market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current retinitis pigmentosa marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the retinitis pigmentosa market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the retinitis pigmentosa market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the retinitis pigmentosa market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of retinitis pigmentosa across the seven major markets?
• What is the number of prevalent cases (2018-2034) of retinitis pigmentosa by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of retinitis pigmentosa by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with retinitis pigmentosa across the seven major markets?
• What is the size of the retinitis pigmentosa patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of retinitis pigmentosa?
• What will be the growth rate of patients across the seven major markets?
   

Retinitis Pigmentosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for retinitis pigmentosa drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinitis pigmentosa market?
• What are the key regulatory events related to the retinitis pigmentosa market?
• What is the structure of clinical trial landscape by status related to the retinitis pigmentosa market?
• What is the structure of clinical trial landscape by phase related to the retinitis pigmentosa market?
• What is the structure of clinical trial landscape by route of administration related to the retinitis pigmentosa market?